Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease

British Journal of Haematology

Volumn 162, Issue 6, 2013, Pages 836-841

  Desai, Payal C ^a   May, Ryan C ^b,c   Jones, Susan K ^a   Strayhorn, Dell ^a   Caughey, Melissa ^a   Hinderliter, Alan ^a   Ataga, Kenneth I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

Hydroxycarbamide; Progression; Pulmonary hypertension; Sickle cell disease; Tricuspid regurgitant jet velocity

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BILIRUBIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE; NITROGEN; UREA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; THROMBOCYTE COUNT; TRICUSPID REGURGITANT JET VELOCITY; TRICUSPID VALVE REGURGITATION; UREA NITROGEN BLOOD LEVEL;

HYDROXYCARBAMIDE; PROGRESSION; PULMONARY HYPERTENSION; SICKLE CELL DISEASE; TRICUSPID REGURGITANT JET VELOCITY;

ADULT; AGED; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYDROXYUREA; HYPERTENSION, PULMONARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TRICUSPID VALVE INSUFFICIENCY; YOUNG ADULT;

EID: 84883273152     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12453     Document Type: Article

References (25)

1. Ataga, K.I., Sood, N., De Gent, G., Kelly, E., Henderson, A.G., Jones, S., Strayhorn, D., Lail, A., Lieff, S. & Orringer, E.P. (2004) Pulmonary hypertension in sickle cell disease. American Journal of Medicine, 117, 665-669.
2. Ataga, K.I., Moore, C.G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A. & Orringer, E.P. (2006) Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British Journal of Haematology, 134, 109-115.
3. Ataga, K.I., Brittain, J.E., Moore, D., Jones, S.K., Hulkower, B., Strayhorn, D., Adam, S., Redding Lallinger, R., Nachman, P. & Orringer, E.P. (2010) Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms like tyrosine kinase 1. European Journal of Haematology, 85, 257-263.
4. Barst, R.J., Mubarak, K.K., Machado, R.F., Ataga, K.I., Benza, R.L., Castro, O., Naeije, R., Sood, N., Swerdlow, P.S. & Hildesheim, M. (2010) Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology, 149, 426-435.
5. Bradford, C.N., Ely, D.R. & Raizada, M.K. (2010) Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Current Hypertension Reports, 12, 212-219.
6. Brun, M., Bourdoulous, S., Couraud, P.O., Elion, J., Krishnamoorthy, R. & Lapoumeroulie, C. (2003) Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal, 3, 215-226.
7. Bunn, H.F., Nathan, D.G., Dover, G.J., Hebbel, R.P., Platt, O.S., Rosse, W.F. & Ware, R.E. (2010) Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, 116, 687-692.
8. Carache, S., Terrin, T.L. & Moore, R.D. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. New England Journal of Medicine, 332, 1317-1322.
9. De Castro, L.M., Jonassaint, J.C., Graham, F.L., Ashley Koch, A. & Telen, M.J. (2008) Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. American Journal of Hematology, 83, 19-25.
10. Falk, R.J., Scheinman, J., Phillips, G., Orringer, E., Johnson, A. & Jennette, J.C. (1992) Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. New England Journal of Medicine, 326, 910-915.
11. Fonseca, G.H., Souza, R., Salemi, V.M., Jardim, C.V. & Gualandro, S.F. (2011) Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. European Respiratory Journal, 39, 112-118.
12. Gladwin, M.T., Shelhamer, J.H., Ognibene, F.P., Pease-Fye, M.E., Nichols, J.S., Link, B., Patel, D.B., Jankowski, M.A., Pannell, L.K., Schechter, A.N. & Rodgers, G.P. (2002) Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. British Journal of Haematology, 116, 436-444.
13. Gladwin, M.T., Sachdev, V., Jison, M.L., Shizukuda, Y., Plehn, J.F., Minter, K., Brown, B., Coles, W.A., Nichols, J.S., Ernst, I., Hunter, L.A., Blackwelder, W.C., Schechter, A.N., Rodgers, G.P., Castro, O. & Ognibene, F.P. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. New England Journal of Medicine, 350, 886-895.
14. Glover, R.E., Corbett, J.T., Burka, L.T. & Mason, R.P. (1999) In vivo production of nitric oxide after administration of cyclohexanone oxime. Chemical Research in Toxicology, 12, 952-957.
15. Hassell, K.L. (2010) Population estimates of sickle cell disease in the U.S. American Journal of Preventive Medicine, 38, S512-S521.
16. Kato, G.J., Martyr, S., Blackwelder, W.C., Nichols, J.S., Coles, W.A., Hunter, L.A., Brennan, M.-L., Hazen, S.L. & Gladwin, M.T. (2005) Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology, 130, 943-953.
17. Kato, G.J., Gladwin, M.T. & Steinberg, M.H. (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews, 21, 37-47.
18. Machado, R.F., Barst, R.J., Yovetich, N.A., Hassell, K.L., Kato, G.J., Gordeuk, V.R., Gibbs, J.S., Little, J.A., Schraufnagel, D.E., Krishnamurti, L., Girgis, R.E., Morris, C.R., Rosenzweig, E.B., Badesch, D.B., Lanzkron, S., Onyekwere, O., Castro, O.L., Sachdev, V., Waclawiw, M.A., Woolson, R., Goldsmith, J.C. & Gladwin, M.T. (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 118, 855-864.
19. Marshall, R.P. (2003) The pulmonary renin-angiotensin system. Current Pharmaceutical Design, 9, 715-722.
20. Mehari, A., Gladwin, M.T., Tian, X., Machado, R.F. & Kato, G.J. (2012) Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA, 307, 1254-1256.
21. Olnes, M., Chi, A., Haney, C., May, R., Minniti, C., Taylor, J. & Kato, G.J. (2009) Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. American Journal of Hematology, 84, 529-531.
22. Parent, F., Bachir, D., Inamo, J., Lionnet, F., Driss, F., Loko, G., Habibi, A., Bennani, S., Savale, L. & Adnot, S. (2011) A hemodynamic study of pulmonary hypertension in sickle cell disease. New England Journal of Medicine, 365, 44-53.
23. Pashankar, F.D., Carbonella, J., Bazzy-Asaad, A. & Friedman, A. (2009) Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. British Journal of Haematology, 144, 736-741.
24. Saleh, A.W., Hillen, H.F. & Duits, A.J. (1999) Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematologica, 102, 31-37.
25. Yock, P.G. & Popp, R.L. (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation, 70, 657-662.